See more : CIMC Enric Holdings Limited (3899.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Oncodesign Société Anonyme (ALONC.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncodesign Société Anonyme, a leading company in the Biotechnology industry within the Healthcare sector.
- DURATEK (8098.TWO) Income Statement Analysis – Financial Results
- Orange Belgium S.A. (OBEL.BR) Income Statement Analysis – Financial Results
- Paradigm Biopharmaceuticals Limited (PBIGF) Income Statement Analysis – Financial Results
- Credicorp Ltd. (0U8N.L) Income Statement Analysis – Financial Results
- Lifestore Financial Group, Inc. (LSFG) Income Statement Analysis – Financial Results
Oncodesign Société Anonyme (ALONC.PA)
About Oncodesign Société Anonyme
Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. Oncodesign Société Anonyme has a strategic partnership with InterSystems for new treatments in the field of oncology; and Covalab. The company also has a collaboration agreement with TiumBio Co., Ltd. for the research and development of fibrosis drug candidates. Oncodesign Société Anonyme was founded in 1995 and is headquartered in Dijon, France.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.21M | 29.60M | 30.62M | 23.80M | 17.72M | 13.10M | 14.52M | 7.19M | 7.34M | 7.25M | 5.66M | 4.56M | 3.80M |
| Cost of Revenue | 16.45M | 15.25M | 16.20M | 16.18M | 14.37M | 9.46M | 9.30M | 7.03M | 5.89M | 5.10M | 3.84M | 3.00M | 2.51M |
| Gross Profit | 19.76M | 14.35M | 14.43M | 7.61M | 3.35M | 3.64M | 5.22M | 155.40K | 1.45M | 2.15M | 1.83M | 1.56M | 1.29M |
| Gross Profit Ratio | 54.58% | 48.48% | 47.11% | 31.99% | 18.91% | 27.76% | 35.96% | 2.16% | 19.69% | 29.61% | 32.25% | 34.25% | 34.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 64.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 64.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 20.48M | 13.17M | 13.72M | 11.26M | 7.66M | 6.44M | 5.73M | 3.75M | 3.40M | 2.17M | 2.82M | 2.75M | 2.69M |
| Operating Expenses | 20.48M | 13.17M | 13.79M | 11.26M | 7.66M | 6.44M | 5.73M | 3.75M | 3.40M | 2.17M | 2.82M | 2.75M | 2.69M |
| Cost & Expenses | 36.92M | 28.42M | 29.98M | 27.45M | 22.02M | 15.90M | 15.03M | 10.79M | 9.29M | 7.28M | 6.66M | 5.75M | 5.20M |
| Interest Income | 405.87K | 7.55K | 0.00 | 0.00 | 0.00 | 0.00 | 253.06K | 92.54K | 31.06K | 41.60K | 8.22K | 155.00 | 620.00 |
| Interest Expense | 890.16K | 317.10K | 223.91K | 415.00K | 65.00K | 55.00K | 42.25K | 26.99K | 22.01K | 53.48K | 20.69K | 23.18K | 36.99K |
| Depreciation & Amortization | 111.94K | 1.16M | 1.55M | 1.20M | 524.00K | 463.00K | 175.90K | 134.60K | 147.11K | 109.25K | 68.49K | 100.48K | 236.46K |
| EBITDA | 669.29K | 3.20M | 3.14M | -1.54M | -4.16M | -2.35M | -321.01K | -3.43M | -1.74M | 160.30K | -1.04M | -586.84K | -1.15M |
| EBITDA Ratio | 1.85% | 10.81% | 10.25% | -6.45% | -23.46% | -17.90% | -2.21% | -47.78% | -23.76% | 2.21% | -18.31% | -12.87% | -30.29% |
| Operating Income | 557.35K | 2.04M | 1.59M | -2.74M | -4.68M | -2.81M | -496.90K | -3.57M | -1.89M | 51.06K | -1.11M | -687.32K | -1.39M |
| Operating Income Ratio | 1.54% | 6.91% | 5.20% | -11.50% | -26.42% | -21.44% | -3.42% | -49.65% | -25.77% | 0.70% | -19.52% | -15.07% | -36.52% |
| Total Other Income/Expenses | -1.61M | -1.32M | -1.22M | -1.22M | 164.00K | -13.00K | -49.19K | -74.13K | -77.20K | -103.57K | -15.06K | -612.05K | -122.77K |
| Income Before Tax | -1.05M | 727.57K | 369.15K | -3.95M | -4.52M | -2.82M | -546.10K | -3.64M | -1.97M | -52.51K | -1.12M | -1.30M | -1.51M |
| Income Before Tax Ratio | -2.91% | 2.46% | 1.21% | -16.60% | -25.49% | -21.53% | -3.76% | -50.68% | -26.82% | -0.72% | -19.79% | -28.49% | -39.75% |
| Income Tax Expense | -44.56K | -375.67K | -255.68K | -1.00K | 256.00K | -3.50M | -1.75M | -1.30M | -949.45K | -789.19K | -557.15K | -361.50K | -499.52K |
| Net Income | -1.01M | 1.10M | 624.83K | -3.95M | -4.77M | 678.00K | 1.20M | -2.35M | -1.02M | 736.68K | -563.64K | -937.88K | -1.01M |
| Net Income Ratio | -2.79% | 3.73% | 2.04% | -16.60% | -26.94% | 5.18% | 8.27% | -32.64% | -13.88% | 10.16% | -9.95% | -20.57% | -26.59% |
| EPS | -0.03 | 0.16 | 0.09 | -0.58 | -0.70 | 0.10 | 0.18 | -0.39 | -0.17 | 0.12 | -0.09 | -0.15 | -0.17 |
| EPS Diluted | -0.03 | 0.16 | 0.09 | -0.58 | -0.70 | 0.10 | 0.18 | -0.39 | -0.17 | 0.12 | -0.09 | -0.15 | -0.17 |
| Weighted Avg Shares Out | 31.43M | 6.83M | 6.82M | 6.82M | 6.85M | 7.07M | 6.82M | 6.06M | 6.06M | 6.06M | 6.06M | 6.06M | 6.06M |
| Weighted Avg Shares Out (Dil) | 31.43M | 6.83M | 6.82M | 6.82M | 6.85M | 7.07M | 6.82M | 6.06M | 6.06M | 6.06M | 6.06M | 6.06M | 6.06M |
Source: https://incomestatements.info
Category: Stock Reports